周三盘中，爵士制药（JAZZ）股价大跌5.04%，投资者对公司最新发布的二季度财报表现出失望情绪。
根据爵士制药周二晚间发布的财报显示，公司二季度每股亏损8.25美元，远超分析师预期的7.62美元亏损。尽管公司总营收为10.5亿美元，略高于分析师预期的10.4亿美元，但巨额亏损仍然引发了市场担忧。更值得注意的是，公司2025财年前六个月累计净亏损高达8.11亿美元，而去年同期还实现了1.54亿美元的净利润。
这份财报反映出爵士制药目前面临的经营困境。尽管公司收入略有增长，但巨额亏损可能影响其未来发展和研发投入。分析人士认为，这可能是导致投资者信心下降，进而引发股价大跌的主要原因。市场将密切关注公司后续的业绩表现和战略调整，以评估其长期发展前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.